

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, 24 April 2025

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (Ley de los Mercados de Valores y de los Servicios de Inversión), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following

OTHER RELEVANT INFORMATION

The Board of Directors of Pharma Mar, S.A., at its meeting held today, has agreed to convene an Ordinary General Shareholders' Meeting to be held at the Auditorio Municipal Villa de Colmenar Viejo, calle Molino de Viento, s/n, 28770 Colmenar Viejo, on 18 June 2025, at 12:00 p.m. on second call, as it is not foreseeable that the quorum for the first call, which has been set for 17 June 2025 at 12:00 p.m., at the same place, will be met.

The items to be transacted at this General Meeting will be as follows:

I. ITEMS SUBMITTED FOR VOTING

First.- To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2024.

Second.- To review and, as the case may be, approve the consolidated non-financial information and sustainability information, included in the Management Report of the Pharma Mar Group, for the fiscal year ended December 31, 2024.

Third.- To review and, as the case may be, approve the proposed application of the Company's results for the year ended December 31, 2024.

Fourth.- To review and, as the case may be, approve the corporate management during the fiscal year 2024.

Fifth.- To review and, as the case may be, approve of the proposed distribution of a dividend out of unrestricted reserves (share premium).

Sixth.- Re-election of Mr. Eduardo Serra Rexach as Director for the statutory period of four years, with the category of Other External Director.

Seventh.- To authorize the Board of Directors, with express power of substitution, to buyback treasury stock, by the Company and/or by its subsidiary companies, under the terms provided by current legislation, with express power to proceed its transfer or amortization with reduction of the share capital number, leaving without effect, in the amount not used, the delegation agreed by the General Shareholders' Meeting of previous year.

Eighth.- Approval of a Plan for 2026 for the delivery of shares of Pharma Mar, S.A. treasury stock to employees and executives of Group companies in order to promote their participation in the share capital and encourage them to remain in the Group.

Ninth.- Approval of Pharma Mar, S.A.'s Directors' Compensation Policy.

Tenth.- To submit the Annual Report on Compensation of Directors of Pharma Mar, S.A. for fiscal year 2024 to an advisory vote (Art. 541.4 of the Spanish Capital Companies Act).

Eleventh.- To authorize the Board of Directors to interpret, remedy, supplement, implement, execute and develop the resolutions adopted by the General Meeting, both to record such resolutions in a public deed and to substitute the powers entrusted thereto by the General Meeting.

II. INFORMATIONAL ITEMS

Twelfth.- Information to the General Meeting, in accordance with the provisions of article 528 of the Spanish Capital Corporations Law, regarding any amendments to the Board of Directors Regulations.

The Board of Directors of Pharma Mar, S.A. has authorised its Chairman to determine the date of publication of the notice of call, which is expected to be published in the next few days, at which time the aforementioned notice and the proposed resolutions to be submitted by the Board to the General Meeting will be sent to the CNMV, and will be made available to shareholders together with the other mandatory documentation relating to the Meeting.